Polypharmacy in Psychiatry Practice, Volume I [[electronic resource] ] : Multiple Medication Use Strategies / / edited by Michael S Ritsner

• Pubblicazione: Dordrecht : , : Springer Netherlands : , : Imprint : Springer, , 2013
• Edizione: 1st ed. 2013.
• Descrizione fisica: 1 online resource (295 p.)
• Disciplina: 615.7/88; 615.788; 616.8918
• Soggetto topico: Medicine; Psychiatry; Pharmacy; Clinical psychology; Medical education; Psychopharmacology; Biomedicine, general; Clinical Psychology; Medical Education
• Persona (resp. second.): RitsnerMichael S
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Polypharmacy in Psychiatry Practice Volume I; About the Editor; Preface; Contents; Contributors; Part I: Polypharmacy Treatment Strategies; Chapter 1 : Multiple Psychiatric Medications Use in Psychiatry: How Rational Can It Be?; 1.1 Introduction; 1.2 Rationale for MMU in HIV; 1.3 Rationale for MMU in Cancer; 1.4 Rationale for MMU in Parkinson's Disease; 1.5 The Principles and the Rationale for MPMU; 1.5.1 Pharmacokinetic Drug Interactions; 1.5.2 Pharmacodynamic Drug Interactions; 1.5.3 Interactions Involving both Pharmacokinetic and Pharmacodynamic Mechanisms ; 1.6 Conclusions and Future DirectionsReferences; Chapter 2: Receptor Binding Targets for Antipsychotic Efficacy; 2.1 Introduction; 2.2 Methods; 2.2.1 Data Analysis; 2.3 Results; 2.4 Discussion; 2.4.1 D3 Dopamine Receptor Provides a Molecular Binding Target for Antipsychotic Efficacy; 2.4.2 Serotonin Receptor Contributions to Antipsychotic Efficacy; 2.5 Limitations; 2.6 Conclusions and Future Directions; References; Chapter 3: Drug Interactions and Polypharmacy; 3.1 Introduction; 3.2 Pharmacodynamic Interactions; 3.2.1 Pharmacodynamic Drug Interaction Classification ; 3.2.2 Time Course of Pharmacodynamic Interactions3.2.3 Serious Pharmacodynamic Interactions; 3.2.3.1 Hypertension and Hypertensive Crisis; 3.2.3.2 Serotonin Syndrome; 3.2.3.3 Bleeding; 3.2.3.4 Psychosis and Extrapyramidal Side Effects; 3.2.3.5 CNS Depression; 3.2.3.6 Anticholinergic Effects; 3.2.3.7 Arrhythmias/QTc Prolongation; 3.3 Pharmacokinetic Drug Interactions; 3.4 Clinical Effects of Drug Interactions; 3.4.1 Risk Factors; 3.5 Drug Interaction Software; 3.6 Prevention and Management of Drug Interactions; 3.7 Resources for Assessing Drug Interactions; 3.8 Conclusions ; Appendix. Commonly Encountered Psychotropic Interactions [ 9, 47, 59, 74 ]References; Chapter 4: Preclinical and Clinical Investigation of Antipsychotic Polypharmacy: What Is the Evidence?; 4.1 Introduction; 4.2 What Is the Preclinical Evidence for Antipsychotic Polypharmacy?; 4.3 Antipsychotic Polypharmacy in Clinical Practice; 4.3.1 Prevalence of Antipsychotic Polypharmacy; 4.3.2 Explaining the Differences in Prevalence of Antipsychotic Polypharmacy Among Studies; 4.3.3 Does the Prevalence of Polypharmacy Depend on the Baseline Antipsychotic Agent? ; 4.3.4 Prevalence of Polypharmacy: Change Over Time4.3.5 Predictors of Polypharmacy; 4.3.5.1 Patient Factors; 4.3.5.2 Setting and Therapists Factors; 4.3.6 Other Factors Associated with Antipsychotic Polypharmacy; 4.3.6.1 Mortality; 4.3.6.2 Increased Total Antipsychotic Dose; 4.3.6.3 Cost; 4.3.6.4 Cognitive Impairment; 4.4 Efficacy of Polypharmacy; 4.4.1 Meta-analyses; 4.4.2 Reviews; 4.4.3 Discontinuation Studies; 4.5 Management of Antipsychotic Polypharmacy; 4.6 Discussing the Evidence; 4.7 Conclusions and Future Directions; References ; Chapter 5: Should High Dose or Very Long-Term Antipsychotic Monotherapy Be Considered Before Antipsychotic Polypharmacy?
• Sommario/riassunto: Despite the large number of psychotropic medications currently available, effective management of mental disorders continues to be a challenging task. Although monotherapy may be desirable, most patients require combinations of two or more psychotropic drugs. Polypharmacy aims to address different aspects of treatment resistance, especially insufficient response of positive and negative symptoms, cognitive disturbances, affective comorbidity, obsessive-compulsive syndromes and side-effects of antipsychotic agents. At the same time, evidence based guidelines in support of polypharmacy, and augmentative strategies are scant. This two-volume collection is the first comprehensive, clinically oriented, reference text on polypharmacy (co-administration of more than one medication) or the use of multiple preparations to treat psychotic, cognitive, mood and anxiety disorders. This collection is divided into four parts. Volume I contains two parts including chapters that serve as an introduction and overview of conceptual issues. Key topics include: rational polypharmacy, receptor binding targets, drug interactions, preclinical and clinical investigations in this field, dosing regimens, multiple medication use in forensic psychiatry, a naturalistic trial, adjunctive strategies, and multiple medication use for the treatment of somatic symptom disorders. Volume II contains two parts that focus on antipsychotic polypharmacy for schizophrenia, and clinical practice in the USA, Czech Republic, Ukraine, and Italy, polypharmacy and associated phenomena, clozapine combinations and the metabolic syndrome. The authors discuss combination therapy for bipolar disorder, major depressive disorder, obsessive-compulsive syndromes in schizophrenia, and potentially inappropriate medication use among elderly patients with dementia. Finally, each volume includes Appendix contains ‘Annotated bibliography on polypharmacy’ and ‘List of Psychotropic Medications’.
• Titolo autorizzato: Polypharmacy in Psychiatry Practice, Volume I
• ISBN: 1-299-40842-7; 94-007-5805-7
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910437844903321
• Lo trovi qui: Univ. Federico II